Sign In  |  Register  |  About Walnut Creek Guide  |  Contact Us

Walnut Creek, CA
September 01, 2020 1:43pm
7-Day Forecast | Traffic

  • Search Hotels in Walnut Creek Guide

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Takeda Pharmaceutical Ltd ADR (NY: TAK )

13.49 +0.11 (+0.82%)
Official Closing Price Updated: 7:00 PM EST, Nov 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Takeda Pharmaceutical Ltd ADR

< Previous 1 2
...
7 8 9 10 11 12 13 14 15
...
17 18 Next >
Novavax Stock Looks Like a Good Value With Its New Combined Vaccine
NVAX stock could be worth 63% more based on its new combination flu and Covid-19 vaccine after passing Phase 1/2 clinical trials. 
Via InvestorPlace
Takeda Announces Approval of Nuvaxovid® COVID-19 Vaccine for Primary and Booster Immunization in Japan
From Takeda Pharmaceutical Company Limited
Via Business Wire
Japan's Health Ministry Panel OKs Approval Of Novavax's COVID-19 Vaccine: Report
Via Benzinga
Takeda’s TAKHZYRO® (lanadelumab-flyo) Prefilled Syringe Now Available for People With Hereditary Angioedema (HAE) Ages 12 Years and Older in the United States
From Takeda Pharmaceutical Company Limited
Via Business Wire
FDA Approves Takeda's Vonvendi As Prophylactic Treatment In Bleeding Disorder
The  
Via Benzinga
Phathom Pharma's Vonoprazan Commercial Preparation Update At Needham Healthcare Conference
Via Benzinga
Cognitive Drugs Market Expected Reach Revenues Of $21 Billion in 2027
Palm Beach, FL – April 13, 2022 – FinancialNewsMedia.com News Commentary – Dementia is the loss of cognitive functioning, thinking, remembering, reasoning, and behavioral abilities to such an extent... 
Via FinancialNewsMedia
Exposures COVID-19
Takeda Announces Completion of Acquisition of Own Shares
From Takeda Pharmaceutical Company Limited
Via Business Wire
The Daily Biotech Pulse: Aeglea Stock Jumps On Inherited Metabolic Disease Data, Partial Hold Lifted On Gilead's 2 Blood Trials, Early Data From Novartis' KRAS Inhibitor And More
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Takeda’s TAKHZYRO® (lanadelumab) Open Label Phase 3 Study Met Its Objectives in Children Ages 2 to <12 Years of Age With Hereditary Angioedema (HAE)
From Takeda Pharmaceutical Company Limited
Via Business Wire
Takeda and the New York Academy of Sciences Announce 2022 Innovators in Science Award Winners
From Takeda Pharmaceutical Company Limited
Via Business Wire
Monday Markets News
Japanese Takeda TAK shares failed to thrive after its edema prevention drug was approved. 
Via Talk Markets
Takeda’s TAKHZYRO® (lanadelumab) Approved in Japan for Prophylaxis Against Acute Attacks of Hereditary Angioedema (HAE)
From Takeda Pharmaceutical Company Limited
Via Business Wire
Takeda's Angioedema Drug Shows Promising Action Against COVID-19 Infection
Takeda Pharmaceutical Co Ltd's (NYSE: TAK) Firazyr (icatibant), used to treat a blood vessel condition called angioedema, has shown promise as a treatment for COVID... 
Via Benzinga
Interim Phase 4 Data Support TAKHZYRO® (lanadelumab) as an Effective Treatment to Reduce Attacks in Hereditary Angioedema Patients
From Takeda Pharmaceutical Company Limited
Via Business Wire
Roche And AstraZeneca Settle Ultomiris Patent Lawsuit
Roche Holdings AG (OTC: RHHBY) has decided to close out a patent infringement lawsuit against AstraZeneca plc (NASDAQ: AZN), centering around the latter's newly... 
Via Benzinga
Takeda Inks $2B Gene Therapy Pact With Code Biotherapeutics
Takeda Pharmaceutical Co Ltd (NYSE: TAK) has signed up for a gene therapy pact, encoding a $2 billion biobucks deal with Code Biotherapeutics across four... 
Via Benzinga
Real-World Analysis Show Takeda's Alofisel Clinical Remission Rate At Six-Months
Takeda Pharmaceutical Co Ltd (NYSE: TAK) announced the first six-month interim analysis results from INSPIRE study evaluating the Real-World Effectiveness and Safety of... 
Via Benzinga
Alofisel®▼ (darvadstrocel) Shows Clinical Remission Rate at Six-Months in the Real-World INSPIRE Study Interim Analysis Consistent with the Pivotal Clinical ADMIRE-CD Study1,2
From Takeda Pharmaceutical Company Limited
Via Business Wire
The Best Russell 2000 Stocks to Buy Before they Rebound
Some of the best stocks in the market are among the best Russell 2000 stocks to buy. Here's a list of a few of those choices. 
Via InvestorPlace
Why Are Seagen Shares Sinking Today?
Seagen Inc (NASDAQ: SGEN) reported Q4 revenues 
Via Benzinga
Take a Leap Into Novavax Stock After Vaccine Sales Start
Novavax is worth speculating on at current levels. NVAX stock has fallen below the $100 mark ahead of its global Covid-19 vaccine launch. 
Via InvestorPlace
A News Blizzard
Markets are still down despite very encouraging news in January when 467,00 new hires got jobs. 
Via Talk Markets
Takeda Delivers Strong Third Quarter FY2021 Results and Raises Full-Year Forecast Reflecting Strong Momentum
From Takeda Pharmaceutical Company Limited
Via Business Wire
FDA Approves Prophylactic Treatment with VONVENDI® [von Willebrand Factor (Recombinant)] for Adult Patients Living with Severe Type 3 von Willebrand Disease (VWD)
From Takeda Pharmaceutical Company Limited
Via Business Wire
Worldwide Adoption of Novavax Vaccines Makes It a Winner
Novavax can still generate billions of dollars of revenue per year from its shot, making NVAX stock quite attractive at its current levels. 
Via InvestorPlace
Takeda Named Global Top Employer for Fifth Consecutive Year
From Takeda Pharmaceutical Company Limited
Via Business Wire
More Serious Matters
Wall Street fell on new worries about inflation and a drop in retail sales levels. 
Via Talk Markets
Denali Stock Tumbles; Why Biogen Isn't The Only Alzheimer's Play Under Pressure
Denali Therapeutics is under pressure after the FDA put its study on hold. 
Via Investor's Business Daily
Interest Rate Hikes And Stocks
Abnormal flooding in northwest Brazil has blocked iron ore mining which resulted in a jump in the price of ore. 
Via Talk Markets
< Previous 1 2
...
7 8 9 10 11 12 13 14 15
...
17 18 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 WalnutCreekGuide.com & California Media Partners, LLC. All rights reserved.